0000070318-20-000019.txt : 20200403 0000070318-20-000019.hdr.sgml : 20200403 20200402191245 ACCESSION NUMBER: 0000070318-20-000019 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200402 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200403 DATE AS OF CHANGE: 20200402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TENET HEALTHCARE CORP CENTRAL INDEX KEY: 0000070318 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 952557091 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-07293 FILM NUMBER: 20771014 BUSINESS ADDRESS: STREET 1: 14201 DALLAS PARKWAY CITY: DALLAS STATE: TX ZIP: 75254 BUSINESS PHONE: 469-893-2200 MAIL ADDRESS: STREET 1: 14201 DALLAS PARKWAY CITY: DALLAS STATE: TX ZIP: 75254 FORMER COMPANY: FORMER CONFORMED NAME: NATIONAL MEDICAL ENTERPRISES INC /NV/ DATE OF NAME CHANGE: 19920703 8-K 1 thc-202042x8k2.htm 8-K Document
false0000070318 0000070318 2020-04-02 2020-04-02 0000070318 exch:XNYS us-gaap:SeniorNotesMember 2020-04-02 2020-04-02 0000070318 exch:XNYS us-gaap:CommonStockMember 2020-04-02 2020-04-02

 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 _______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 _______________
Date of Report:  April 2, 2020
(Date of earliest event reported)
 _______________
TENET HEALTHCARE CORPORATION
(Exact name of Registrant as specified in its charter)
 
 
 
 
 
Nevada
 
1-7293
 
95-2557091
(State of Incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification Number)
14201 Dallas Parkway
Dallas, Texas 75254
(Address of principal executive offices, including zip code)
(469) 893-2200
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common stock, $0.05 par value
 
THC
 
New York Stock Exchange
6.875% Senior Notes due 2031
 
THC31
 
New York Stock Exchange
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ¨
 





The information in this Current Report on Form 8-K and the press releases attached hereto as Exhibit 99.1 and Exhibit 99.2 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified therein as being incorporated by reference.
Item 7.01.
Regulation FD Disclosure.
On April 2, 2020, Tenet Healthcare Corporation (the “Company”) issued a press release announcing the commencement of a private placement offering of $500 million in aggregate principal amount of its senior secured first lien notes due 2025. A copy of the press release is being furnished as Exhibit 99.1 attached hereto and is incorporated herein by reference.
Additionally, on April 2, 2020, the Company issued a press release announcing the pricing of and upsizing to $700 million in aggregate principal amount of its 7.500% senior secured first lien notes due 2025 (the “notes”). The closing of the sale of the notes is expected to occur on April 7, 2020, and is subject to customary closing conditions. A copy of the press release is being furnished as Exhibit 99.2 attached hereto and is incorporated herein by reference.
The Company intends to use the net proceeds from the sale of the notes, after payment of fees and expenses, to repay a portion of the $500 million aggregate principal amount of borrowings outstanding under its senior secured revolving credit facility or for general corporate purposes.
The notes will be guaranteed by certain of the Company’s subsidiaries and secured on a first lien priority basis by a pledge of the capital stock and other ownership interests of certain of the Company’s subsidiaries. The notes will be effectively senior to the Company’s existing and future indebtedness secured on a more junior basis, as well as unsecured indebtedness and other liabilities, to the extent of the value of the collateral securing such borrowings.
Item 9.01.
Financial Statements and Exhibits.
 
(d)
Exhibits






SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
TENET HEALTHCARE CORPORATION
 
 
 
 
Date:
April 2, 2020
By:
/s/ Anthony Shoemaker
 
 
 
Anthony Shoemaker
 
 
 
Vice President, Assistant General Counsel and Corporate Secretary






EX-99.1 2 thc-202042ex991launch.htm EXHIBIT 99.1 Exhibit
Exhibit 99.1

 
Tenet Announces $500 Million Private Offering of Senior Secured Notes
DALLAS – April 2, 2020 Tenet Healthcare Corporation (NYSE: THC) announces a private placement offering of $500 million in aggregate principal amount of newly issued senior secured first lien notes maturing in 2025 (the “notes”). Completion of the offering is subject to, among other things, pricing and market conditions.
Tenet intends to use the net proceeds from the sale of the notes, after payment of fees and expenses, to repay a portion of the $500 million aggregate principal amount of borrowings outstanding under its senior secured revolving credit facility or for general corporate purposes. Tenet is also seeking an amendment to its senior secured revolving credit facility, which will include increasing borrowing capacity under the facility to $2.0 billion (up from $1.5 billion).
The notes will be guaranteed by certain of Tenet’s subsidiaries and secured on a first lien priority basis by a pledge of the capital stock and other ownership interests of certain of Tenet’s subsidiaries. The notes will be effectively senior to Tenet’s existing and future indebtedness secured on a more junior basis, as well as unsecured indebtedness and other liabilities, to the extent of the value of the collateral securing such borrowings.
The notes to be offered will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any other state securities laws. As a result, they may not be offered or sold in the United States or to any U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the notes will be offered only to persons reasonably believed to be “qualified institutional buyers” under Rule 144A of the Securities Act or, outside the United States, to persons other than “U.S. persons” in compliance with Regulation S under the Securities Act. A confidential offering memorandum for the notes will be made available to such eligible persons. The offering will be conducted in accordance with the terms and subject to the conditions set forth in such offering memorandum.
This news release is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of, these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Cautionary Statement
This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company's expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature



address matters that are, to different degrees, uncertain. Particular uncertainties that could cause the Company's actual results to be materially different than those expressed in the Company's forward-looking statements include, but are not limited to, the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2019 and other filings with the Securities and Exchange Commission.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas, with 113,000 employees. Through an expansive care network that includes United Surgical Partners International, we operate 65 hospitals and approximately 500 other healthcare facilities, including surgical hospitals, ambulatory surgery centers, urgent care and imaging centers and other care sites and clinics. We also operate Conifer Health Solutions, which provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other customers. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve.
###
Investor Contact:
Regina Nethery
469-893-2387
regina.nethery@tenethealth.com
Media Contact:
Lesley Bogdanow
469-893-2640
mediarelations@tenethealth.com
This release contains “forward-looking statements” – that is, statements that relate to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include, but are not limited to, uncertainties about the timing or amount of the proposed offering, whether the offering will be completed, the expected purposes of the offering and the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2019 and other filings with the Securities and Exchange Commission.


EX-99.2 3 thc-202042ex992price.htm EXHIBIT 99.2 Exhibit
Exhibit 99.2

 
Tenet Announces Upsizing and Pricing of its $700 Million Private Offering of Senior Secured Notes
DALLAS – April 2, 2020 Tenet Healthcare Corporation (NYSE: THC) today announced the pricing of the previously announced private placement offering and has agreed to issue and sell $700 million in aggregate principal amount of senior secured first lien notes due on April 1, 2025, which will bear interest at a rate of 7.500% per annum (the “notes”). The aggregate principal amount of notes to be issued in the offering was increased to $700 million from the previously announced $500 million. Completion of the notes offering is expected to occur on April 7, 2020, and is subject to, among other things, standard closing and market conditions.
Tenet intends to use the net proceeds from the sale of the notes, after payment of fees and expenses, to repay a portion of the $500 million aggregate principal amount of borrowings outstanding under its senior secured revolving credit facility or for general corporate purposes. Tenet is also seeking an amendment to its senior secured revolving credit facility, which will include increasing borrowing capacity under the facility to $2.0 billion (up from $1.5 billion).
The notes will be guaranteed by certain of Tenet’s subsidiaries and secured on a first lien priority basis by a pledge of the capital stock and other ownership interests of certain of Tenet’s subsidiaries. The notes will be effectively senior to Tenet’s existing and future indebtedness secured on a more junior basis, as well as unsecured indebtedness and other liabilities, to the extent of the value of the collateral securing such borrowings.
The notes to be offered will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any other state securities laws. As a result, they may not be offered or sold in the United States or to any U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the notes will be offered only to persons reasonably believed to be “qualified institutional buyers” under Rule 144A of the Securities Act or, outside the United States, to persons other than “U.S. persons” in compliance with Regulation S under the Securities Act. A confidential offering memorandum for the notes will be made available to such eligible persons. The offering will be conducted in accordance with the terms and subject to the conditions set forth in such offering memorandum.
This news release is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of, these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Cautionary Statement
This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company's expected



future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause the Company's actual results to be materially different than those expressed in the Company's forward-looking statements include, but are not limited to, the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2019 and other filings with the Securities and Exchange Commission.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas, with 113,000 employees. Through an expansive care network that includes United Surgical Partners International, we operate 65 hospitals and approximately 500 other healthcare facilities, including surgical hospitals, ambulatory surgery centers, urgent care and imaging centers and other care sites and clinics. We also operate Conifer Health Solutions, which provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other customers. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve.
###
Investor Contact:
Regina Nethery
469-893-2387
regina.nethery@tenethealth.com
Media Contact:
Lesley Bogdanow
469-893-2640
mediarelations@tenethealth.com


EX-101.SCH 4 thc-20200402.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 thc-20200402_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 thc-20200402_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 thc-20200402_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Entities [Table] Entities [Table] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Exchange [Domain] Exchange [Domain] New York Stock Exchange NEW YORK STOCK EXCHANGE, INC. [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common stock, $0.05 par value Common Stock [Member] 6.875% Senior Notes due 2031 Senior Notes [Member] Entity Information [Line Items] Entity Information [Line Items] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 8 thc-20200402_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT JSON 9 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "thc-202042x8k2.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 3, "dts": { "calculationLink": { "local": [ "thc-20200402_cal.xml" ] }, "definitionLink": { "local": [ "thc-20200402_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "thc-202042x8k2.htm" ] }, "labelLink": { "local": [ "thc-20200402_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "thc-20200402_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "thc-20200402.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 32, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 3, "nsprefix": "thc", "nsuri": "http://www.tenethealth.com/20200402", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "thc-202042x8k2.htm", "contextRef": "D2020Q2SD2", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information Document", "role": "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "thc-202042x8k2.htm", "contextRef": "D2020Q2SD2", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]", "terseLabel": "New York Stock Exchange" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common stock, $0.05 par value" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Senior Notes [Member]", "terseLabel": "6.875% Senior Notes due 2031" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.tenethealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information Document
Apr. 02, 2020
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Apr. 02, 2020
Entity Registrant Name TENET HEALTHCARE CORP
Entity Incorporation, State or Country Code NV
Entity File Number 1-7293
Entity Tax Identification Number 95-2557091
Entity Address, Address Line One 14201 Dallas Parkway
Entity Address, City or Town Dallas
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75254
City Area Code 469
Local Phone Number 893-2200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000070318
Amendment Flag false
New York Stock Exchange | Common stock, $0.05 par value  
Entity Information [Line Items]  
Title of 12(b) Security Common stock, $0.05 par value
Trading Symbol THC
Security Exchange Name NYSE
New York Stock Exchange | 6.875% Senior Notes due 2031  
Entity Information [Line Items]  
Title of 12(b) Security 6.875% Senior Notes due 2031
Trading Symbol THC31
Security Exchange Name NYSE
XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 3 95 1 false 3 0 false 0 false false R1.htm 0001000 - Document - Document and Entity Information Document Sheet http://www.tenethealth.com/role/DocumentAndEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports thc-202042x8k2.htm thc-20200402.xsd thc-20200402_cal.xml thc-20200402_def.xml thc-20200402_lab.xml thc-20200402_pre.xml thc-202042ex991launch.htm thc-202042ex992price.htm http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://xbrl.sec.gov/exch/2019-01-31 true true ZIP 12 0000070318-20-000019-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000070318-20-000019-xbrl.zip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thc-202042x8k2_htm.xml IDEA: XBRL DOCUMENT 0000070318 2020-04-02 2020-04-02 0000070318 us-gaap:SeniorNotesMember exch:XNYS 2020-04-02 2020-04-02 0000070318 us-gaap:CommonStockMember exch:XNYS 2020-04-02 2020-04-02 false 0000070318 8-K 2020-04-02 TENET HEALTHCARE CORP NV 1-7293 95-2557091 14201 Dallas Parkway Dallas TX 75254 469 893-2200 Common stock, $0.05 par value THC NYSE 6.875% Senior Notes due 2031 THC31 NYSE false false false false false EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}